172 related articles for article (PubMed ID: 20420372)
1. Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
Rickert EL; Oriana S; Hartman-Frey C; Long X; Webb TT; Nephew KP; Weatherman RV
Bioconjug Chem; 2010 May; 21(5):903-10. PubMed ID: 20420372
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
3. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
4. A new selective fluorescent probe based on tamoxifen.
Ho LA; Thomas E; McLaughlin RA; Flematti GR; Fuller RO
Bioorg Med Chem Lett; 2016 Oct; 26(20):4879-4883. PubMed ID: 27662800
[TBL] [Abstract][Full Text] [Related]
5. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384.
Auger S; Mérand Y; Pelletier JD; Poirier D; Labrie F
J Steroid Biochem Mol Biol; 1995 Jun; 52(6):547-65. PubMed ID: 7779759
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
Roos W; Oeze L; Löser R; Eppenberger U
J Natl Cancer Inst; 1983 Jul; 71(1):55-9. PubMed ID: 6575210
[TBL] [Abstract][Full Text] [Related]
8. Loss of antagonistic activity of tamoxifen by replacement of one N-methyl of its side chain by fluorinated residues.
Agouridas V; Laïos I; Cleeren A; Kizilian E; Magnier E; Blazejewski JC; Leclercq G
Bioorg Med Chem; 2006 Nov; 14(22):7531-8. PubMed ID: 16870452
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
10.
Díaz M; Lobo F; Hernández D; Amesty Á; Valdés-Baizabal C; Canerina-Amaro A; Mesa-Herrera F; Soler K; Boto A; Marín R; Estévez-Braun A; Lahoz F
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069498
[TBL] [Abstract][Full Text] [Related]
11. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
12. Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.
May FE; Westley BR
J Biol Chem; 1987 Nov; 262(33):15894-9. PubMed ID: 2824472
[TBL] [Abstract][Full Text] [Related]
13. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
Kraft KS; Ruenitz PC; Bartlett MG
J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
[TBL] [Abstract][Full Text] [Related]
14. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
Castro-Rivera E; Safe S
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
[TBL] [Abstract][Full Text] [Related]
15. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
17. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines.
Néri C; Berthois Y; Schatz B; Drieu K; Martin PM
Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 7-hydroxy-3,4-diphenyl-1,2-dihydroisoquinolines as new 4-hydroxytamoxifen analogues.
Kihara M; Ikeuchi M; Yamauchi A; Nukatsuka M; Matsumoto H; Toko T
Chem Pharm Bull (Tokyo); 1997 May; 45(5):939-43. PubMed ID: 9178528
[TBL] [Abstract][Full Text] [Related]
20. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
Maximov PY; Myers CB; Curpan RF; Lewis-Wambi JS; Jordan VC
J Med Chem; 2010 Apr; 53(8):3273-83. PubMed ID: 20334368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
